Literature DB >> 10941827

Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination.

A Tsuboi1, Y Oka, H Ogawa, O A Elisseeva, H Li, K Kawasaki, K Aozasa, T Kishimoto, K Udaka, H Sugiyama.   

Abstract

We recently have reported that Wilms' tumor gene WT1 is highly expressed not only in leukemias but also in various types of solid tumors and that WT1 protein is a novel tumor antigen against which cytotoxic T lymphocytes (CTLs) can be elicited by immunization with 9-mer WT1 peptides capable of binding to major histocompatibility complex (MHC) class I molecules. In the present study, plasmid DNA encoding murine full-length WT1 protein was injected intramuscularly into C57BL/6 mice. The mice vaccinated with the WT1 plasmid DNA elicited CTLs against the WT1 protein, and the CTLs specifically killed WT1-expressing tumor cells in a MHC class I-restricted manner. Furthermore, the vaccinated mice rejected the challenges of WT1-expressing tumor cells and survived with no signs of autoimmunity caused by the CTLs. These results demonstrated that vaccination with the WT1 plasmid DNA can elicit CTL responses specific for the WT1 protein, resulting in the acquisition of rejection activity against challenges of WT1-expressing tumor cells. This WT1 DNA vaccination may find clinical application for various types of solid tumors as well as leukemias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10941827     DOI: 10.1023/a:1006637529995

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  44 in total

Review 1.  Tumor antigens.

Authors:  J L Urban; H Schreiber
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 2.  DNA vaccines.

Authors:  J B Ulmer; J C Sadoff; M A Liu
Journal:  Curr Opin Immunol       Date:  1996-08       Impact factor: 7.486

3.  Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.

Authors:  H T Maecker; D T Umetsu; R H DeKruyff; S Levy
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

Review 4.  T cell defined tumor antigens.

Authors:  B J Van den Eynde; P van der Bruggen
Journal:  Curr Opin Immunol       Date:  1997-10       Impact factor: 7.486

5.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

6.  Gene vaccination with naked plasmid DNA: mechanism of CTL priming.

Authors:  M Corr; D J Lee; D A Carson; H Tighe
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

7.  Expression of the Wilms' tumor gene (WT1) in human leukemias.

Authors:  H Miwa; M Beran; G F Saunders
Journal:  Leukemia       Date:  1992-05       Impact factor: 11.528

8.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02

9.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

Review 3.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

4.  Tumor-associated antigens in breast cancer.

Authors:  Carmen Criscitiello
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

5.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

6.  Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Authors:  Takuya Osada; Christopher Y Woo; Matthew McKinney; Xiao Yi Yang; Gangjun Lei; Heather G Labreche; Zachary C Hartman; Donna Niedzwiecki; Nelson Chao; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

8.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Tetsuya Taguchi; Tadashi Osaki; Taiichi Kyo; Hiroko Nakajima; Olga A Elisseeva; Yusuke Oji; Manabu Kawakami; Kazuhiro Ikegame; Naoki Hosen; Satoshi Yoshihara; Fei Wu; Fumihiro Fujiki; Masaki Murakami; Tomoki Masuda; Sumiyuki Nishida; Toshiaki Shirakata; Shin-Ichi Nakatsuka; Ayako Sasaki; Keiko Udaka; Hiroo Dohy; Katsuyuki Aozasa; Shinzaburo Noguchi; Ichiro Kawase; Haruo Sugiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

Review 9.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 10.  Cancer immunotherapy targeting WT1 protein.

Authors:  Haruo Sugiyama
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.